Disease progression model for Clinical Dementia Rating-Sum of Boxes in mild cognitive impairment and Alzheimer's subjects from the Alzheimer's Disease Neuroimaging Initiative.

摘要: Background The objective of this analysis was to develop a nonlinear disease progression model, using an expanded set covariates that captures the longitudinal Clinical Dementia Rating Scale-Sum Boxes (CDR-SB) scores. These were derived from Alzheimer's Disease Neuroimaging Initiative ADNI-1 study, 301 and mild cognitive impairment patients who followed for 2-3 years. Methods model describes rate baseline score as function covariates. tested fell into five groups: a) hippocampal volume; b) serum cerebrospinal fluid (CSF) biomarkers; c) demographics apolipoprotein Epsilon 4 (ApoE4) allele status; d) tests; e) state comedications. Results Covariates associated with severity state, volume, comedication use. influenced by CSF biomarkers, Trail-Making Test part A score, delayed logical memory test current level measured CDR-SB. dependent on severity, intermediate scores around inflection point 10 exhibiting high rate. CDR-SB in typical patient, late disease, estimated be approximately 0.5 1.4 points/year, respectively. Conclusions In conclusion, terms changes its dependency novel biomarkers included discriminate subjects progressors nonprogressors. Therefore, may utilized optimizing study designs, through patient population enrichment clinical trial simulations.